Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.Analysts called the stock reaction overdone, while Chief Executive Vlad Coric ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar ...

Xenon Pharmaceuticals Inc (XENE) showcases robust pipeline progress and financial stability, while addressing challenges in ...

they're not just for SLS AMG owners or Back to the Future fans anymore. Kia is bringing its KV7 crossover concept to the 2011 Detroit Auto Show, and the ingress/egress on it looks to be pretty simple.

QRL-101-03 (NCT06532396) is a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial evaluating the safety, tolerability, and PK of QRL-101 in up to 60 healthy ...

This would be the ongoing development of BHV-700, which is the company's selective Kv7 activator. That's because it is currently in the process of evaluating several studies for this entire program.

“We also expect multiple regulatory filings in 2025 coming out of our early-stage portfolio – which includes Kv7 and Nav1.7 candidates that are progressing through IND-enabling studies – to support ...